The greatest risk of grade 3–4 PAEs in patients with skin cancer was from anti-PDL1 plus targeted therapy drug, which differed significantly from the other interventions except for anti-CTLA4 plus chemotherapy and anti-PD1 plus anti-CTLA4. The gene discussed is CTLA4; the disease is skin cancer.